Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
STERIS plc is a global provider of infection prevention and other procedural products and services, primarily serving the healthcare, pharmaceutical, medical device, and life sciences industries. The company’s core mission is to help customers create safer environments for patients and healthcare professionals through sterilization, disinfection, and contamination control solutions. Its revenue is driven by a combination of capital equipment sales, consumables, service contracts, and recurring maintenance and compliance services.
The company traces its roots to Steris Corporation, founded in the United States in 1985, and later restructured as STERIS plc, an Ireland-domiciled public limited company. Over time, STERIS expanded through organic growth and strategic acquisitions, broadening its portfolio across healthcare facilities, pharmaceutical manufacturing, and research environments. The company is recognized for its integrated approach, combining equipment, consumables, and long-term service relationships that create high customer retention and recurring revenue streams.
Business Operations
STERIS operates through three primary business segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment provides capital equipment such as sterilizers, surgical tables, washers, and endoscopy products, along with consumables and service programs for hospitals and ambulatory surgery centers. The Applied Sterilization Technologies (AST) segment delivers outsourced terminal sterilization services, laboratory testing, and microbiological consulting for medical device, pharmaceutical, and consumer product manufacturers. The Life Sciences segment supplies contamination control solutions, including sterilization equipment, cleanroom products, and ongoing services for pharmaceutical production and research facilities.
Operations span both domestic and international markets, with manufacturing, service centers, and laboratories across multiple regions. The company controls proprietary sterilization technologies, process validation expertise, and service infrastructure that supports long-term customer contracts. STERIS also operates through numerous wholly owned subsidiaries that support regional sales, manufacturing, and service delivery, reinforcing its vertically integrated operating model.
Strategic Position & Investments
STERIS’s strategic direction focuses on expanding recurring revenue, increasing penetration in regulated industries, and leveraging its service-based business model. Growth initiatives emphasize investment in installed base expansion, digital workflow solutions, and regulatory-driven services where compliance requirements support long-term demand. The company has consistently prioritized high-margin service offerings and consumables that complement its capital equipment portfolio.
A key strategic move was the acquisition of Cantel Medical, which significantly expanded STERIS’s infection prevention footprint, particularly in endoscopy and dental markets. The company continues to invest in capacity expansion within Applied Sterilization Technologies (AST), particularly for medical device and pharmaceutical customers. Emerging areas of focus include advanced sterilization modalities, cleanroom and aseptic processing solutions, and enhanced data-driven compliance and monitoring tools.
Geographic Footprint
STERIS is headquartered in Ireland, with significant operational and managerial presence in the United States, which represents its largest revenue-generating market. The company maintains a broad footprint across North America, Europe, and Asia-Pacific, serving customers in both developed and emerging healthcare markets. Manufacturing plants, service centers, and laboratory facilities are strategically located to support regional regulatory requirements and customer proximity.
International operations play a critical role in supporting global pharmaceutical and medical device manufacturers, particularly through the Applied Sterilization Technologies (AST) segment. STERIS’s global reach enables it to participate in cross-border supply chains and multinational clinical and manufacturing environments, reinforcing its position as a global infection prevention partner.
Leadership & Governance
STERIS is led by an experienced executive team with deep backgrounds in healthcare technology, industrial services, and regulated manufacturing. The leadership emphasizes operational excellence, customer-centric innovation, and disciplined capital allocation. Governance is structured to support long-term value creation, regulatory compliance, and risk management across global operations.
Key executives include:
- Daniel A. Carestio – President and Chief Executive Officer
- Michael J. Tokich – Senior Vice President and Chief Financial Officer
- Karen L. Kocher – Senior Vice President and Chief Legal Officer
- Sharon L. Fox – Senior Vice President and President, Healthcare
- John J. Dubay – Senior Vice President and President, Applied Sterilization Technologies (AST)